vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and Ostin Technology Group Co., Ltd. (OST). Click either name above to swap in a different company.
ASCENTAGE PHARMA GROUP INTERNATIONAL is the larger business by last-quarter revenue ($32.6M vs $20.8M, roughly 1.6× Ostin Technology Group Co., Ltd.).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
Ostin Technology Group Co., Ltd. is a provider of display and interactive technology solutions. It develops and manufactures touch panels, interactive whiteboards and custom display modules, serving consumer electronics, education and commercial segments across Asia Pacific, North America and European markets.
AAPG vs OST — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $20.8M |
| Net Profit | $11.4M | $-5.2M |
| Gross Margin | 90.7% | 9.1% |
| Operating Margin | — | -23.4% |
| Net Margin | — | -24.8% |
| Revenue YoY | — | 39.2% |
| Net Profit YoY | — | -11.6% |
| EPS (diluted) | — | $-2.98 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $32.6M | — | ||
| Q1 25 | — | $20.8M | ||
| Q1 24 | — | $15.0M |
| Q2 25 | $11.4M | — | ||
| Q1 25 | — | $-5.2M | ||
| Q1 24 | — | $-4.6M |
| Q2 25 | 90.7% | — | ||
| Q1 25 | — | 9.1% | ||
| Q1 24 | — | 5.9% |
| Q2 25 | — | — | ||
| Q1 25 | — | -23.4% | ||
| Q1 24 | — | -25.3% |
| Q2 25 | — | — | ||
| Q1 25 | — | -24.8% | ||
| Q1 24 | — | -31.0% |
| Q2 25 | — | — | ||
| Q1 25 | — | $-2.98 | ||
| Q1 24 | — | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.7M |
| Total Assets | — | $52.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q1 25 | — | $1.7M | ||
| Q1 24 | — | $1.7M |
| Q2 25 | — | — | ||
| Q1 25 | — | $2.7M | ||
| Q1 24 | — | $10.3M |
| Q2 25 | — | — | ||
| Q1 25 | — | $52.6M | ||
| Q1 24 | — | $51.4M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAPG
| Products | $29.7M | 91% |
| Others | $2.9M | 9% |
OST
Segment breakdown not available.
